Apigenin
description1
description2
Specification
Test Items |
Standard |
Apigenin (CAS: 520-36-5) |
98% by HPLC |
Loss on drying |
≤5.0% |
Residue on ignition |
≤0.5% |

Abundant Natural Source

Multi-Target Action

High Safety Profile
1. Molecular Target Network
2.Pharmacokinetics
Absorption
Low oral bioavailability (<5%), metabolized by gut microbiota to active derivatives.
Distribution
Widely distributed in liver, lungs, brain (BBB penetration ~3%).
Metabolism
Hepatic glucuronidation (UGT1A1/1A9), hydroxylation (CYP1A2).
Excretion
Primarily biliary (80%), urinary excretion <5%.
Clinical Applications
Indication |
Mechanism |
Clinical Stage |
Adjuvant Breast Cancer Therapy |
ERβ agonism + CDK4/6 inhibition |
Phase II Trials |
Anxiety Disorders |
GABAₐ receptor modulation |
Preclinical |
Diabetic Complications |
AGEs formation inhibition |
Phase I Trials |

Antitumor

Neuroprotection

Dietary Supplement
Safety Evaluation
Adverse Effects
System |
Incidence |
Manifestations |
Gastrointestinal |
5% |
Mild nausea |
Elevated Liver Enzymes |
<1% |
Reversible ALT↑ |
Hypersensitivity |
Rare |
Skin erythema |
Drug Interactions
CYP1A2 Substrates (e.g., caffeine): Metabolism slowed (AUC↑40%).
Warfarin: May enhance anticoagulation (mechanism unclear).
Research Progress Green max
Novel Formulations
Phospholipid Complexes: Bioavailability increased to 25%.
Gold Nanoparticle Carriers: 10× higher tumor targeting (preclinical).
New Indications
Alzheimer’s Disease: Reduces Tau phosphorylation (animal models).
COVID-19: Inhibits 3CL protease (IC₅₀=45 μM).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.


